Thermo Fisher Scientific Q2 2026 Earnings Analysis
Impossibile aggiungere al carrello
Puoi avere soltanto 50 titoli nel carrello per il checkout.
Riprova più tardi
Riprova più tardi
Rimozione dalla Lista desideri non riuscita.
Riprova più tardi
Non è stato possibile aggiungere il titolo alla Libreria
Per favore riprova
Non è stato possibile seguire il Podcast
Per favore riprova
Esecuzione del comando Non seguire più non riuscita
Thermo Fisher Scientific Q2 2026 Earnings Analysis
-
Letto da:
-
Di:
Groups: HEALTHCARE (https://betafinch.com/groups/HEALTHCARE)
──────────
**Beta Finch: Thermo Fisher Scientific (TMO) Q2 2026 Earnings Breakdown**
ALEX: Welcome to Beta Finch, your AI-powered earnings breakdown. Today we're digging into Thermo Fisher Scientific's second quarter 2026 results, and Jordan, this is a genuinely strong print to sink our teeth into.
JORDAN: Before we get into it, quick disclaimer for everyone listening. This podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.
ALEX: Right, with that out of the way, let's talk numbers. Thermo Fisher posted revenue of $11.99 billion, up 10% year-over-year. Adjusted operating income jumped 15% to $2.73 billion, and adjusted EPS grew 13% to $6.03 a share.
JORDAN: And what jumps out to me is that this wasn't a "beat on cost-cutting" quarter — this was a genuine top-line story. Organic revenue growth came in at 5%, which management explicitly said was about 2 points ahead of their own prior guidance. Margins expanded too — adjusted operating margin hit 22.8%, up 90 basis points. That's the kind of quarter where basically everything worked at once.
ALEX: Let's break down where that growth came from. All four end markets grew mid-single-digits or better. Pharma and biotech — their biggest bucket at roughly 60% of revenue — grew mid-single digits, led by bioproduction and clinical research. Industrial and applied also grew mid-single digits, diagnostics and healthcare grew mid-single digits, and even academic and government, which has been the soft spot for a while, returned to growth, albeit low single digits.
JORDAN: That academic and government comeback is worth sitting with for a second. CEO Marc Casper was careful not to declare victory there — he said they want to see it "more broad-based" before calling it a real trend. But the U.S. turned slightly positive, Europe was actually quite strong, and interestingly China stayed muted in that segment specifically. So it's a cautious green shoot, not a full recovery.
ALEX: Speaking of China — it's about 7.5% of total revenue and grew low single digits, which is its first return to growth in a while. Casper credited that to pharma/biotech and industrial and applied demand, while academic spending there remains flat. He was clear it's not yet accretive to overall company growth, but the trajectory is improving.
JORDAN: Now let's talk capital moves, because there's a lot going on here. Thermo Fisher closed the Clario acquisition in late March — that's digital clinical trial endpoint data — and it had a strong first full quarter of ownership. They also closed the filtration and separation business, formerly part of 3M/Solventum, which is showing strong demand and they're actually adding capacity.
ALEX: And on the flip side, they're divesting their microbiology business, expected to close in Q3. That business did about $645 million in revenue in 2025. They used the anticipated proceeds to fund a $1 billion share buyback in the quarter — so essentially pre-funding the repurchase ahead of the deal closing.
JORDAN: That divestiture does create some near-term drag, worth flagging for anyone modeling this out — management said it reduces 2026 revenue by about $200 million net of retained channel sales, and dings adjusted EPS by about $0.05 this year, growing to roughly $0.15 dilutive in the first full year after close.
ALEX: Which makes the guidance raise even more impressive, because it absorbs that headwind and still goes up. New revenue guidance is $47.4 to $48.1 billion, representing 6-8% reported growth. Organic growth guidance moved to "about 4%" for the full year — they kept the 3-4% range but said they now expect to land at the top of it. Adjusted EPS guidance rose to $24.93 to $2
This episode includes AI-generated content.
adbl_web_anon_alc_button_suppression_t1
Ancora nessuna recensione